Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | TGM1 | P22735 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26467780 | 1.00 | PTPN1 (0.33) | PTPN1ALDH1A1F13A1TGM2TGM1 | |
| SCHEMBL6796073 | 0.96 | PTPN1 (0.35) | PTPN1ALDH1A1F13A1TGM2TGM1 | |
| SCHEMBL26466302 | 0.88 | ALDH1A1 (0.33) | PTPN1ALDH1A1F13A1TGM2TGM1 | |
| SCHEMBL26465895 | 0.84 | MEN1 (0.32) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL26465918 | 0.84 | MEN1 (0.32) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL5201608 | 0.84 | MEN1 (0.33) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL5201612 | 0.84 | MEN1 (0.33) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL22968909 | 0.83 | PTPN1 (0.34) | PTPN1ALDH1A1F13A1TGM2TGM1 | |
| SCHEMBL21367006 | 0.83 | PTPN1 (0.34) | PTPN1ALDH1A1F13A1TGM2TGM1 | |
| SCHEMBL21367005 | 0.83 | PTPN1 (0.34) | PTPN1ALDH1A1F13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4087583-A1 | ARGINASE INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | PTPN1 2395/4885ALDH1A1 383/4885F13A1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.